FDA approves new drugs for pediatric type 2 diabetes treatment.

1 min read
Source: FDA.gov
FDA approves new drugs for pediatric type 2 diabetes treatment.
Photo: FDA.gov
TL;DR

The FDA has approved Jardiance and Synjardy as new oral therapies to treat pediatric type 2 diabetes in children aged 10 and older. Type 2 diabetes is a chronic and progressive condition that affects the body's ability to use insulin normally, leading to high levels of glucose in the blood. Empagliflozin, the active ingredient in Jardiance and Synjardy, works by increasing the excretion of glucose in the urine. The incidence of type 2 diabetes in children is expected to continue increasing, and these approvals provide much-needed additional treatment options for children with type 2 diabetes.

Share this article

Want the full story? Read the original reporting

Read on FDA.gov